Investigation of the Mechanism and Effect of Enalapril, Angiotensin-Converting Enzyme (ACE) Inhibitor, on Proliferation, Apoptosis, and Migration in Colorectal Cancer Cells

Document Type : Original Article (s)

Authors

1 PhD Student, Department of Biology, School of Sciences, Mashhad Branch, Islamic Azad University, Mashhad, Iran

2 Professor, Department of Biology AND Research Center for Animal Development Applied Biology, Mashhad Branch, Islamic Azad University, Mashhad, Iran

3 Professor, Department of Physiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

4 Assistant Professor, Department of Medical Genetics, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

5 Assistant Professor, Department of Medical Biochemistry, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Background: Colorectal cancer is one of the most common cancers in Iran, and despite high cure rate, it still has high mortality. Some studies have shown that angiotensin-converting enzyme (ACE) inhibitors are effective in treating cancer in addition to treating hypertension. The aim of this study was to investigate the effect of enalapril on the proliferation, migration, and expression of ACE, angiotensin II type I receptor (AT1R), vascular endothelial growth factor-A (VEGF-A), and transforming growth factor beta 1 (TGF-β1) genes in colorectal cancer cells.Methods: In this study, the effect of enalapril on the survival rate of CT26, HT29, and SW480 colorectal cancer cells was determined using MTT assay, cell migration was assayed using migration assay technique, and cell cycle assay was performed using flow cytometry. Expression of matrix metalloproteinase 3 (MMP3), MMP9, and epithelial cadherin (E-cadherin), ACE, AT1R, VEGF-A, and TGF-β1 genes were also evaluated using real-time polymerase chain reaction (PCR) technique and reactive oxygen species in these three cell lines.Findings: Enalapril had anti-proliferative and anti-migrate effect on all three colorectal cancer cell lines compared to the control group. Expression of E-cadherin, MMP3, and MMP9 genes significantly decreased after treatment with enalapril (P < 0.001). Expression of ACE, AT1R, VEGF-A, and TGF-β1 genes showed a significant decrease in the three cell lines, and the level of reactive oxygen species significantly increased in the three cell lines compared to the control group.Conclusion: Given the various anticancer effects of enalapril, it seems that at least alongside standard chemotherapy drugs, enalapril may be useful in the treatment of colorectal cancer.

Keywords

References

  1. Stoeltzing O, Liu W, Reinmuth N, Parikh A, Ahmad SA, Jung YD, et al. New approaches to the treatment of hepatic malignancies angiogenesis and antiangiogenic therapy of colon cancer liver metastasis. Ann Surg Oncol 2003; 10(7): 722-33.
  2. Neo JH, Malcontenti-Wilson C, Muralidharan V, Christophi C. Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases. J Gastroenterol Hepatol 2007; 22(4): 577-84.
  3. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 2016; 66(4): 271-89.
  4. Wegman-Ostrosky T, Soto-Reyes E, Vidal-Millan S, Sanchez-Corona J. The renin-angiotensin system meets the hallmarks of cancer. J Renin Angiotensin Aldosterone Syst 2015; 16(2): 227-33.
  5. Nakamura K, Yaguchi T, Ohmura G, Kobayashi A, Kawamura N, Iwata T, et al. Involvement of local renin-angiotensin system in immunosuppression of tumor microenvironment. Cancer Sci 2018; 109(1): 54-64.
  6. Lindberg H, Nielsen D, Jensen BV, Eriksen J, Skovsgaard T. Angiotensin converting enzyme inhibitors for cancer treatment? Acta Oncol 2004; 43(2): 142-52.
  7. Massague J. G1 cell-cycle control and cancer. Nature 2004; 432(7015): 298-306.
  8. Moses HL, Yang EY, Pietenpol JA. TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights. Cell 1990; 63(2): 245-7.
  9. Gomez RA, Tufro-McReddie A, Everett AD, Pentz ES. Ontogeny of renin and AT1 receptor in the rat. Pediatr Nephrol 1993; 7(5): 635-8.
  10. Kang NS, Yim HE, Bae IS, Choi JH, Choi BM, Yoo KH, et al. ACE inhibition modulates transforming growth factor-beta receptors in the young rat. Pediatr Nephrol 2003; 18(9): 865-71.
  11. Massague J. The transforming growth factor-beta family. Annu Rev Cell Biol 1990; 6: 597-641.
  12. Shimizu Y, Amano H, Ito Y, Betto T, Yamane S, Inoue T, et al. The role of angiotensin II in liver metastasis formation fromcolorectal cancer. Kitasato Med J 2017; 47: 43-51.
  13. Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB, Johnson MD, et al. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 1996; 98(3): 671-9.
  14. Chen L, Re RN, Prakash O, Mondal D. Angiotensin-converting enzyme inhibition reduces neuroblastoma cell growth rate. Proc Soc Exp Biol Med 1991; 196(3): 280-3.
  15. Yoshiji H, Kuriyama S, Kawata M, Yoshii J, Ikenaka Y, Noguchi R, et al. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res 2001; 7(4): 1073-8.
  16. Salehi E, Amjadi FS, Khazaei M. Angiogenesis in health and disease: Role of vascular endothelial growth factor (VEGF). J Isfahan Med Sch 2011; 29(132): 312-26. [In Persian].
  17. Fendrich V, Chen NM, Neef M, Waldmann J, Buchholz M, Feldmann G, et al. The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. Gut 2010; 59(5): 630-7.
  18. Erstad DJ, Cusack JC. Targeting the NF-kappaB pathway in cancer therapy. Surg Oncol Clin N Am 2013; 22(4): 705-46.
  19. Neo JH, Ager EI, Angus PW, Zhu J, Herath CB, Christophi C. Changes in the renin angiotensin system during the development of colorectal cancer liver metastases. BMC Cancer 2010; 10: 134.
  20. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25(4): 581-611.
  21. Rhodes DR, Ateeq B, Cao Q, Tomlins SA, Mehra R, Laxman B, et al. AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proc Natl Acad Sci USA 2009; 106(25): 10284-9.
  22. Harrison-Bernard LM, El-Dahr SS, O'Leary DF, Navar LG. Regulation of angiotensin II type 1 receptor mRNA and protein in angiotensin II-induced hypertension. Hypertension 1999; 33(1 Pt 2): 340-6.
  23. Fang QQ, Wang XF, Zhao WY, Ding SL, Shi BH, Xia Y, et al. Angiotensin-converting enzyme inhibitor reduces scar formation by inhibiting both canonical and noncanonical TGF-beta1 pathways. Sci Rep 2018; 8(1): 3332.
  24. Tahergorabi Z, Khazaei M. The relationship between inflammatory markers, angiogenesis, and obesity. ARYA Atheroscler 2013; 9(4): 247-53.
  25. Sun F, Sun H, Zheng X, Yang G, Gong N, Zhou H, et al. Angiotensin-converting enzyme inhibitors decrease the incidence of radiation-induced pneumonitis among lung cancer patients: A systematic review and meta-analysis. J Cancer 2018; 9(12): 2123-31.
  26. Clark R, Wong K, Fan S, Chin J, Izawa J, Power N. Does the Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Improve Survival in Bladder Cancer? EMJ Urol 2018; 6(1): 90-7.
  27. Vinson GP, Barker S, Puddefoot JR. The renin-angiotensin system in the breast and breast cancer. Endocr Relat Cancer 2012; 19(1): R1-19.
  28. Gandini S, Palli D, Spadola G, Bendinelli B, Cocorocchio E, Stanganelli I, et al. Anti-hypertensive drugs and skin cancer risk: A review of the literature and meta-analysis. Crit Rev Oncol Hematol 2018; 122: 1-9.
  29. Menter AR, Carroll NM, Sakoda LC, Delate T, Hornbrook MC, Jain RK, et al. Effect of angiotensin system inhibitors on survival in patients receiving chemotherapy for advanced non-small-cell lung cancer. Clin Lung Cancer 2017; 18(2): 189-97.
  30. Smith TA, Phyu SM, Akabuogu EU. Effects of administered cardioprotective drugs on treatment response of breast cancer cells. Anticancer Res 2016; 36(1): 87-93.
Journal of Isfahan Medical School
Volume 38, Issue 581 - Serial Number 581
May and June 2020
Pages 442-449

Files

History

  • Receive Date: 07 March 2020
  • Revise Date: 13 May 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics